期刊
CURRENT TREATMENT OPTIONS IN ONCOLOGY
卷 19, 期 12, 页码 -出版社
SPRINGER
DOI: 10.1007/s11864-018-0593-2
关键词
Programmed death ligand-1; Immunotherapy; Gynecologic cancer; Ovarian cancer; Endometrial cancer; Cervical cancer
类别
Opinion statementActivity of PD-1 and PD-L1 inhibitors has been demonstrated in ovarian, endometrial, and cervical cancer, with a tolerable side effect profile and the highest response rate seen in mismatch repair-deficient endometrial cancers. Other biomarkers are under active investigation. Tumor testing for mismatch repair deficiency or high microsatellite instability for treatment with pembrolizumab should be considered an option for all women with progressive gynecologic malignancy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据